@article{8bfe185c030543cba3c21c1639ad8d7a,
title = "Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy",
keywords = "IgA nephropathy, glomerular disease, glucocorticoids, gut-associated lymphoid tissue",
author = "Karthik Tennankore",
note = "Publisher Copyright: {\textcopyright} 2022 International Society of Nephrology",
year = "2023",
month = feb,
doi = "10.1016/j.kint.2022.09.017",
language = "English",
volume = "103",
pages = "391--402",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",
}